Steven Gendreau

2.3k total citations
26 papers, 1.1k citations indexed

About

Steven Gendreau is a scholar working on Molecular Biology, Pulmonary and Respiratory Medicine and Oncology. According to data from OpenAlex, Steven Gendreau has authored 26 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Molecular Biology, 16 papers in Pulmonary and Respiratory Medicine and 10 papers in Oncology. Recurrent topics in Steven Gendreau's work include PI3K/AKT/mTOR signaling in cancer (9 papers), Cancer Genomics and Diagnostics (6 papers) and Prostate Cancer Treatment and Research (6 papers). Steven Gendreau is often cited by papers focused on PI3K/AKT/mTOR signaling in cancer (9 papers), Cancer Genomics and Diagnostics (6 papers) and Prostate Cancer Treatment and Research (6 papers). Steven Gendreau collaborates with scholars based in United States, United Kingdom and Spain. Steven Gendreau's co-authors include Joel H. Rothman, Ivan P. Moskowitz, Jill M. Spoerke, Daniel Maslyar, Junko Aimi, Mark R. Lackner, Johann S. de Bono, Premal H. Patel, Christophe Massard and Sergio Bracarda and has published in prestigious journals such as Nature Communications, Journal of Clinical Oncology and PLoS ONE.

In The Last Decade

Steven Gendreau

25 papers receiving 1.1k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Steven Gendreau United States	15	559	494	424	358	169	26	1.1k
Dineli Wickramasinghe United States	17	953 1.7×	312 0.6×	359 0.8×	161 0.4×	54 0.3×	24	1.6k
Chiara Luise Italy	13	1.5k 2.6×	104 0.2×	669 1.6×	312 0.9×	79 0.5×	16	1.9k
Atish D. Choudhury United States	16	892 1.6×	654 1.3×	568 1.3×	472 1.3×	15 0.1×	79	1.7k
Reyno Delrosario United States	17	1.1k 2.0×	147 0.3×	655 1.5×	372 1.0×	12 0.1×	20	1.7k
Gerald Chu United States	5	924 1.7×	51 0.1×	234 0.6×	195 0.5×	165 1.0×	14	1.1k
Katti Jessen United States	12	1.3k 2.3×	157 0.3×	389 0.9×	184 0.5×	14 0.1×	27	1.6k
Paula I. González-Ericsson United States	21	709 1.3×	410 0.8×	935 2.2×	368 1.0×	8 0.0×	54	1.7k
Christopher J. Sarkisian United States	6	920 1.6×	131 0.3×	719 1.7×	238 0.7×	19 0.1×	6	1.3k
Shinichi Yabuuchi Japan	15	761 1.4×	118 0.2×	654 1.5×	449 1.3×	27 0.2×	27	1.4k
Wenlai Zhou United States	13	1.4k 2.5×	426 0.9×	161 0.4×	252 0.7×	13 0.1×	13	1.8k

Countries citing papers authored by Steven Gendreau

Since Specialization

Citations

This map shows the geographic impact of Steven Gendreau's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Steven Gendreau with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Steven Gendreau more than expected).

Fields of papers citing papers by Steven Gendreau

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Steven Gendreau. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Steven Gendreau. The network helps show where Steven Gendreau may publish in the future.

Co-authorship network of co-authors of Steven Gendreau

This figure shows the co-authorship network connecting the top 25 collaborators of Steven Gendreau. A scholar is included among the top collaborators of Steven Gendreau based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Steven Gendreau. Steven Gendreau is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Daemen, Anneleen, Jill M. Spoerke, Wei Zhou, et al.. (2020). Abstract P2-11-05: ER pathway activity signature as a biomarker for endocrine agent GDC-9545. Cancer Research. 80(4_Supplement). P2–11. 1 indexed citations

Goodall, Jane, Zoe J. Assaf, Zhen Shi, et al.. (2020). Circulating tumor DNA (ctDNA) dynamics associate with treatment response and radiological progression-free survival (rPFS): Analyses from a randomized phase II trial in metastatic castration-resistant prostate cancer (mCRPC).. Journal of Clinical Oncology. 38(15_suppl). 5508–5508. 11 indexed citations

Chen, Xiaoji, Ching‐Wei Chang, Jill M. Spoerke, et al.. (2019). Low-pass Whole-genome Sequencing of Circulating Cell-free DNA Demonstrates Dynamic Changes in Genomic Copy Number in a Squamous Lung Cancer Clinical Cohort. Clinical Cancer Research. 25(7). 2254–2263. 54 indexed citations

Bono, Johann S. de, Ugo De Giorgi, Daniel Nava Rodrigues, et al.. (2018). Randomized Phase II Study Evaluating Akt Blockade with Ipatasertib, in Combination with Abiraterone, in Patients with Metastatic Prostate Cancer with and without PTEN Loss. Clinical Cancer Research. 25(3). 928–936. 227 indexed citations

Kang, Yoon‐Koo, Matthew Chau Hsien Ng, Hyun Cheol Chung, et al.. (2018). A phase II, randomised study of mFOLFOX6 with or without the Akt inhibitor ipatasertib in patients with locally advanced or metastatic gastric or gastroesophageal junction cancer. European Journal of Cancer. 108. 17–24. 38 indexed citations

Schöffski, Patrick, Sara Cresta, Ingrid A. Mayer, et al.. (2018). A phase Ib study of pictilisib (GDC-0941) in combination with paclitaxel, with and without bevacizumab or trastuzumab, and with letrozole in advanced breast cancer. Breast Cancer Research. 20(1). 109–109. 67 indexed citations

Wongchenko, Matthew, Doron Lipson, Travis Clark, et al.. (2018). Abstract 2964: On-treatment changes in circulating tumor DNA (ctDNA) level as an early predictor of clinical outcome in the LOTUS randomized phase 2 trial of 1st-line ipatasertib (IPAT) + paclitaxel (PAC) for metastatic triple-negative breast cancer (mTNBC). Cancer Research. 78(13_Supplement). 2964–2964. 1 indexed citations

Djalilvand, Azita, et al.. (2018). Abstract 4531: Development of a companion diagnostic assay for the detection of phosphatase and tensin (PTEN) protein loss and treatment with ipatasertib in metastatic castration-resistant prostatic cancer (mCRPC). Cancer Research. 78(13_Supplement). 4531–4531. 1 indexed citations

Bono, Johann S. de, Sergio Bracarda, K.N. Chi, et al.. (2017). Randomized phase III trial of ipatasertib vs. placebo, plus abiraterone and prednisone/prednisolone, in men with asymptomatic or mildly symptomatic previously untreated metastatic castrate-resistant prostate cancer (mCRPC). Annals of Oncology. 28. v290–v290. 3 indexed citations

10.

Schleifman, Erica, Michelle Nahas, M. Kennedy, et al.. (2017). Abstract P6-07-08: The complete spectrum of ESR1 mutations from 7590 breast cancer tumor samples. Cancer Research. 77(4_Supplement). P6–7.

11.

Greene, Stephanie, Angel E. Dago, Yipeng Wang, et al.. (2016). Chromosomal Instability Estimation Based on Next Generation Sequencing and Single Cell Genome Wide Copy Number Variation Analysis. PLoS ONE. 11(11). e0165089–e0165089. 37 indexed citations

12.

Bono, Johann S. de, Ugo De Giorgi, Christophe Massard, et al.. (2016). PTEN loss as a predictive biomarker for the Akt inhibitor ipatasertib combined with abiraterone acetate in patients with metastatic castration-resistant prostate cancer (mCRPC). Annals of Oncology. 27. vi243–vi243. 40 indexed citations

13.

Vuylsteke, Peter, Manon Huizing, Katarína Petráková, et al.. (2016). Pictilisib PI3Kinase inhibitor (a phosphatidylinositol 3-kinase [PI3K] inhibitor) plus paclitaxel for the treatment of hormone receptor-positive, HER2-negative, locally recurrent, or metastatic breast cancer: interim analysis of the multicentre, placebo-controlled, phase II randomised PEGGY study. Annals of Oncology. 27(11). 2059–2066. 91 indexed citations

14.

Spoerke, Jill M., Steven Gendreau, Kimberly Walter, et al.. (2016). Heterogeneity and clinical significance of ESR1 mutations in ER-positive metastatic breast cancer patients receiving fulvestrant. Nature Communications. 7(1). 11579–11579. 219 indexed citations

15.

Gendreau, Steven, Stephen Johnston, Peter Schmid, et al.. (2016). Abstract PD6-03: High prevalence and clonal heterogeneity of ESR1 mutations (mt) in circulating tumor DNA (ctDNA) from patients (pts) enrolled in FERGI, a randomized phase II study testing pictilisib (GDC-0941) in combination with fulvestrant (F) in pts that failed a prior aromatase inhibitor (AI). Cancer Research. 76(4_Supplement). PD6–3. 2 indexed citations

16.

Wen, Patrick Y., Antonio Omuro, Tracy T. Batchelor, et al.. (2009). Abstract B265: A Phase 1 safety and pharmacokinetic study of XL765 (SAR245409), a novel PI3K/TORC1/TORC2 inhibitor, in combination with temozolomide (TMZ) in patients (pts) with malignant glioma. Molecular Cancer Therapeutics. 8(12_Supplement). B265–B265. 3 indexed citations

17.

Trowe, Torsten, Sotiria Boukouvala, Richard E. Cutler, et al.. (2008). EXEL-7647 Inhibits Mutant Forms of ErbB2 Associated with Lapatinib Resistance and Neoplastic Transformation. Clinical Cancer Research. 14(8). 2465–2475. 94 indexed citations

18.

Fukuyama, Masamitsu, Steven Gendreau, W. Brent Derry, & Joel H. Rothman. (2003). Essential embryonic roles of the CKI-1 cyclin-dependent kinase inhibitor in cell-cycle exit and morphogenesis in C. elegans. Developmental Biology. 260(1). 273–286. 49 indexed citations

19.

Heid, Paul J., et al.. (2001). The Zinc Finger Protein DIE-1 Is Required for Late Events during Epithelial Cell Rearrangement in C. elegans. Developmental Biology. 236(1). 165–180. 52 indexed citations

20.

Gendreau, Steven, Ivan P. Moskowitz, Rebecca M. Terns, & Joel H. Rothman. (1994). The Potential to Differentiate Epidermis Is Unequally Distributed in the AB Lineage during Early Embryonic Development in C. elegans. Developmental Biology. 166(2). 770–781. 30 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact